Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol

• Published in: BMJ open Vol. 8; no. 12; p. e023636
• Main Authors: Nomura, Akihiro, Tada, Hayato, Okada, Hirofumi, Nohara, Atsushi, Ishikawa, Hideki, Yoshimura, Kenichi, Kawashiri, Masa-aki
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.12.2018; BMJ Publishing Group
• Subjects: Adult; Age Distribution; Aged; Atherosclerosis; Cardiovascular disease; Cardiovascular Medicine; Cholesterol; Cholesterol, LDL - blood; Cholesterol, LDL - genetics; Clinical trials; Consent; Coronary Artery Disease - epidemiology; Coronary Artery Disease - etiology; Coronary Artery Disease - physiopathology; Coronary vessels; Education; Female; Gene Expression Regulation; Genetic Testing; Genetic Variation; Health risk assessment; Heart; Hospitals; Hospitals, University; Humans; Hyperlipoproteinemia Type II - complications; Hyperlipoproteinemia Type II - diagnosis; Hyperlipoproteinemia Type II - genetics; Incidence; Japan; Lipids; Low density lipoprotein; Male; Middle Aged; Mutation; Mutation - genetics; Patient satisfaction; Plasma; Prognosis; Reference Values; Risk Assessment; Sex Distribution; Statins; Statistics, Nonparametric; Waiting Lists; Japan; genetic counseling; cardiovascular risk; genetic testing; familial hypercholesterolemia
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2018-023636

IntroductionFamilial hypercholesterolemia (FH) is an autosomal-dominant inherited genetic disease. High-throughput sequencing quickly and comprehensively detects causative variants of FH-related genes (LDLR, PCSK9, APOB and LDLRAP1). Although the presence of causative variants in FH-related genes correlates with future cardiovascular events, it remains unclear whether detection of causative gene mutation and disclosure of its associated cardiovascular risk affects outcomes in patients with FH. Therefore, this study intends to evaluate the efficacy of counselling future cardiovascular risk based on genetic testing in addition to standard patients’ education programme in patients with FH.Methods and analysisA randomised, waiting-list controlled, open-label, single-centre trial will be conducted. We will recruit patients with clinically diagnosed FH without previous history of coronary heart disease from March 2018 to December 2019, and we plan to follow up participants until March 2021. For the intervention group, we will perform genetic counselling and will inform an estimated future cardiovascular risk based on individuals’ genetic testing results. The primary endpoint of this study is the plasma low-density lipoprotein cholesterol level at 24 weeks after randomisation. The secondary endpoints assessed at 24 and 48 weeks are as follows: blood test results; smoking status; changes of lipid-lowering agents’ regimen and Patients Satisfaction Questionnaire Short Form scores among the four groups divided by the presence of genetic counselling and genetic status of FH.Ethics and disseminationThis study will be conducted in compliance with the Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects and all other applicable laws and guidelines in Japan. This study protocol was approved by the IRB at Kanazawa University. We will disseminate the final results at international conferences and in a peer-reviewed journal.Trial registration numberUMIN000029375.